Quantifying allergen-specific IgE by ImmunoCAP fluoroenzyme immunoassay
Specific IgE serum testing begins with a standard venipuncture — no allergen exposure to the patient is required, unlike skin prick testing. This makes serum IgE testing the preferred first-line option for patients with dermatographism, extensive eczema, on antihistamines, or too young/fearful for skin testing.
Skin prick testing (SPT) remains the fastest, most sensitive in vivo method for detecting IgE-mediated sensitization, but it requires viable mast cells in the skin, cessation of antihistamines for 3–7 days, and direct allergen exposure — all of which are impractical or unsafe in some patients.
Served by an in vitro alternative, specific IgE (sIgE) serum testing measures circulating allergen-specific IgE directly in blood, with no risk of anaphylaxis, no antihistamine washout needed, and no interference from dermatographism or extensive eczema/dermatitis that would confound a skin read.
Indications favoring serum testing: infants and young children, patients on chronic antihistamines or beta-blockers, uncontrolled eczema, dermatographism, history of anaphylaxis to the suspected allergen (avoiding re-exposure), and patients unable to cooperate with skin testing.
Serum (not plasma) is preferred: anticoagulants used for plasma collection (heparin, EDTA) can interfere with the solid-phase binding chemistry of downstream fluoroenzyme immunoassays. Blood is collected into a clot-activator or serum-separator tube (SST), allowed to clot for 30–60 minutes at room temperature, then centrifuged.
Centrifugation at ~1,500×g for 10 minutes pellets erythrocytes, leukocytes, and platelets, leaving cell-free serum containing the full spectrum of circulating immunoglobulins — IgG (~75% of total Ig, ~10 mg/mL), IgA, IgM, and IgE. IgE is the least abundant immunoglobulin class by mass (typically <0.001% of total serum protein) yet is the analyte of interest, so the downstream assay must have very high analytical sensitivity to detect it against a large background of IgG.
Serum is stable refrigerated (2–8°C) for several days or frozen (−20°C) for long-term storage; repeated freeze-thaw cycles are avoided to preserve antibody integrity.
IgE is produced by plasma cells after class-switch recombination driven by IL-4/IL-13 signaling in a Th2-skewed immune response. Once secreted, IgE binds with extraordinarily high affinity (Ka ~10¹⁰ M⁻¹) to the high-affinity FcεRI receptor on mast cells and basophils, where it persists for weeks to months — far longer than its serum half-life of ~2–3 days.
The pool of IgE circulating freely in serum is therefore only a fraction of the total IgE in the body; most is already receptor-bound in tissue. Nonetheless, serum sIgE levels correlate well with tissue-bound, allergen-reactive IgE and are a validated, standardized, quantitative proxy for allergic sensitization used across major clinical guidelines (AAAAI, EAACI).
The defining innovation of the ImmunoCAP platform (Phadia/Thermo Fisher) over earlier RAST (radioallergosorbent test) assays is its three-dimensional cellulose sponge solid phase, which increases allergen-binding capacity roughly 100-fold compared to flat paper-disc solid phases, dramatically improving analytical sensitivity and dynamic range.
The original radioallergosorbent test (RAST), introduced in 1967, coupled allergen to flat cellulose paper discs and used a radiolabeled anti-IgE antibody for detection. It was semi-quantitative, had a narrow dynamic range, and relied on radioactive isotopes requiring special handling and disposal.
The ImmunoCAP system replaced the flat disc with a three-dimensional, highly porous cellulose sponge derivative packed inside a small plastic "cap." The sponge structure vastly increases the effective surface area available for allergen coupling, allowing far more allergen molecules — and therefore far more capacity to capture specific IgE — per test. This translates directly into a wider quantitative dynamic range (0.1 to >100 kUA/L) and improved precision at both low and high antibody concentrations.
Allergen (whole extract, or a single purified/recombinant allergen component such as Ara h2) is covalently coupled to the cellulose matrix via cyanogen bromide or similar chemistry, creating a stable, reusable solid phase specific to one allergen per cap.
Diluted patient serum is pipetted into the ImmunoCAP and incubated with gentle agitation. Any IgE antibody in the serum whose paratope (antigen-binding site) is complementary to an epitope on the immobilized allergen will bind, forming an allergen–IgE immune complex fixed to the solid phase.
This is a classic mass-action binding equilibrium: [allergen-IgE complex] increases with total specific IgE concentration in serum, following a saturable binding curve (comparable to Michaelis-Menten kinetics) rather than a strictly linear relationship — which is why raw fluorescence signal must be converted through a nonlinear, multi-point calibration curve to report kUA/L.
Critically, only IgE that recognizes the specific coupled allergen is captured — the vast excess of non-specific IgG, IgA, IgM, and irrelevant IgE clones in serum remains unbound and is removed in the next step. This specificity is what allows the assay to quantify a single allergen-specific antibody population out of the entire circulating antibody repertoire.
Traditional "whole extract" allergen tests (e.g., total peanut extract) measure IgE against the full mixture of proteins in the source material, some of which are clinically important (e.g., Ara h2, a peanut storage protein strongly linked to severe reactions) and some of which are cross-reactive, low-risk pan-allergens (e.g., profilins, PR-10 proteins shared across pollens and plant foods).
Component-resolved diagnostics (CRD) test IgE against individual purified or recombinant allergen molecules, improving specificity: a patient sensitized only to birch pollen PR-10 homologs (e.g., peanut Ara h8) is at low risk for a systemic peanut reaction, whereas sensitization to Ara h2 storage protein correlates strongly with clinical peanut allergy. This distinction is central to modern risk stratification and reduces unnecessary food avoidance and unnecessary oral food challenges.
After a wash step removes every unbound serum protein, the assay must reveal how much specific IgE was actually captured. This is achieved with a second antibody — an enzyme-conjugated anti-human-IgE — that binds exclusively to the captured IgE, forming a solid-phase "sandwich" complex whose enzyme content is directly proportional to bound specific IgE.
This step converts an invisible binding event (allergen-specific IgE attached to a solid phase) into a measurable signal. A monoclonal or polyclonal anti-human-IgE antibody, conjugated to an enzyme label (β-galactosidase in the ImmunoCAP system; alkaline phosphatase or horseradish peroxidase in other platforms), is added to the washed solid phase.
The anti-IgE conjugate binds specifically to the constant (Fc) region of any IgE molecule already captured on the allergen — it cannot bind IgG, IgA, or IgM, and it cannot bind free allergen. The result is a three-layer "sandwich": solid-phase allergen → patient specific IgE → enzyme-labeled anti-IgE. Because each captured IgE molecule can bind (in principle) one or more labeled anti-IgE molecules, the amount of enzyme now immobilized on the solid phase is stoichiometrically related to the amount of specific IgE originally present in the serum.
Between each incubation, unbound reagents are washed away with a buffered wash solution, typically over 3–4 cycles. This washing is what allows the assay to distinguish signal from noise: without it, unbound enzyme-labeled anti-IgE floating free in solution would generate fluorescence regardless of whether any specific IgE was actually captured, producing false-positive results.
Insufficient washing is a recognized source of assay imprecision; automated ImmunoCAP instruments (e.g., Phadia 100/250, Phadia 1000/5000) standardize wash volume, timing, and aspiration to minimize carryover and ensure reproducibility between runs, operators, and instruments — an important advantage of the automated fluoroenzyme platform over manual RAST-era assays.
A well-designed anti-IgE conjugate must be highly specific for IgE constant-region epitopes not shared with other immunoglobulin classes, and must not bind Fc receptors non-specifically. Manufacturers validate conjugate specificity against high-titer IgG samples and IgE-deficient sera to confirm minimal cross-reactivity.
Rheumatoid factor (anti-IgG autoantibodies) and heterophile antibodies are known interferents in some immunoassay formats; ImmunoCAP's washing and blocking reagents are formulated to minimize such interference, though extremely elevated total IgE or unusual paraproteinemias can occasionally cause spurious results, which is why results are always interpreted alongside clinical history rather than in isolation.
The final chemical step converts the bound enzyme label into a quantifiable optical signal. A non-fluorescent substrate is added; the immobilized enzyme catalyzes its conversion into a fluorescent product, and the instrument measures emitted light — the physical basis of the "F" in ImmunoCAP's fluoroenzyme immunoassay (FEIA) methodology.
β-galactosidase bound to the solid phase hydrolyzes the substrate 4-methylumbelliferyl-β-D-galactoside (4-MUG) into galactose and 4-methylumbelliferone (4-MU), a small molecule that fluoresces brightly (excitation ~365 nm, emission ~445 nm) once cleaved from its non-fluorescent parent compound.
Over a fixed incubation window, the rate of 4-MU generation is proportional to the quantity of active enzyme present, which in turn is proportional to the amount of specific IgE captured in Stage 3. The reaction is stopped at a defined time point (typically with a sodium carbonate stop solution that also raises pH to maximize 4-MU fluorescence), and the plate/cap is read in a fluorometer.
This enzymatic amplification step is what gives the assay its sensitivity: each single enzyme molecule can turn over many thousands of substrate molecules per minute, amplifying a small number of captured IgE molecules into a large, easily measured fluorescent signal — analogous to signal amplification in an ELISA.
Raw fluorescence (relative fluorescence units, RFU) is not itself the reported result. Each assay run includes a calibration curve constructed from a set of reference standards (traceable to the WHO IgE International Reference Preparation, 2nd IRP 75/502) spanning the reportable range, typically 0.1–100 kUA/L. The instrument fits a smoothed, non-linear (typically 4-parameter logistic) calibration curve to these standards and interpolates the patient's RFU value against that curve to produce a kUA/L result.
At very high specific IgE concentrations, the fluorescence signal approaches saturation as the finite allergen-binding capacity of the solid phase is exhausted (a ceiling effect) — this is why the RFU-to-concentration relationship flattens at high concentrations and why samples above the top calibrator may require dilution and re-testing to obtain an accurate quantitative value above 100 kUA/L.
The final fluorescence measurement is converted through the stored calibration curve into a quantitative specific IgE concentration (kUA/L), then binned into a semi-quantitative CAP class (0–6). Neither the raw number nor the class alone predicts clinical allergy with certainty — both must be interpreted alongside allergen type, patient age, and exposure history.
The CAP class (0 through 6) is a historical convention for reporting sIgE results in discrete bands, inherited from the original RAST scoring system. A higher class indicates a higher probability that the patient is truly sensitized and a generally higher likelihood of clinical reactivity on exposure — but class number does NOT reliably predict the severity of a reaction if one occurs. A patient with Class 2 peanut IgE can still have anaphylaxis; a patient with Class 5 can have no symptoms at all.
Because of this, modern allergy practice increasingly reports the exact kUA/L value alongside (or instead of) the class, and interprets it using allergen-specific predictive value cutoffs derived from oral food challenge studies rather than the class number alone.
For several major food allergens, prospective studies correlating sIgE level with double-blind placebo-controlled oral food challenge (DBPCFC) outcomes have established concentration thresholds above which the probability of a clinical reaction exceeds 95%:
• Peanut: ≥14 kUA/L → ~95% PPV (Sampson, J Allergy Clin Immunol 2001) • Egg (age ≥2 years): ≥7 kUA/L → ~98% PPV • Egg (age <2 years): ≥2 kUA/L → ~95% PPV • Milk: ≥15 kUA/L → ~95% PPV • Fish: ≥20 kUA/L → ~95% PPV
These cutoffs are allergen-specific and were derived from specific pediatric cohorts; they should not be extrapolated across allergens or populations without caution. For inhalant allergens (dust mite, cat, birch pollen), sIgE correlates with sensitization and symptom likelihood but PPV cutoffs for a defined "reaction" are less standardized, since inhalant challenge testing is less commonly performed than food challenge.
A positive specific IgE result indicates immunological sensitization — the presence of allergen-specific antibody — but sensitization alone does not equal clinical allergy. Up to 50% of sensitized individuals may tolerate the allergen without symptoms on exposure, particularly at low kUA/L values (Class 1–2).
This is why sIgE testing is recommended only for allergens suggested by clinical history (targeted testing), not as an undirected screening panel: broad, unguided panels increase the rate of clinically irrelevant positive results, unnecessary dietary restriction, and patient anxiety. The gold standard for confirming a food allergy diagnosis, when the sIgE/history correlation is ambiguous, remains the physician-supervised oral food challenge.
Serial sIgE measurement over months to years is used clinically to track the natural history of an allergy. Declining sIgE levels in milk, egg, soy, and wheat allergy often (though not always) accompany the acquisition of tolerance, especially in children, and can help time a supervised oral food challenge to confirm resolution.
In contrast, peanut, tree nut, and shellfish allergies are more often persistent into adulthood, and a falling sIgE level alone is not sufficient justification to reintroduce the food without a physician-supervised challenge, since even low sIgE levels do not fully exclude the risk of a reaction.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|